目的:探讨扶正固本方对原发性肝癌经肝动脉化疗栓塞术后患者无进展生存期和生存质量的影响。方法:将2019年1月至2020年3月收治的90例原发性肝癌患者随机分成对照组和观察组,2组患者均采用肝动脉化疗栓塞术治疗,对照组患者术后给予抑酸、保肝、吸氧等对症处理,观察组患者术后联合中药扶正固本方口服治疗,均治疗8周。观察2组患者治疗前后中医证候积分、血清癌抗原19-9(CA19-9)、甲胎蛋白(AFP)水平、无进展生存期(PFS)、半年生存率和生存质量改善状况,比较2组患者临床疗效和Ⅲ度及以上的毒副反应情况。结果:治疗后,2组患者肝脏肿块、胁肋疼痛、脘腹胀满、形体消瘦、恶心呕吐、神疲无力证侯积分及血清CA19-9、AFP水平均明显降低(P＜0.05),且观察组患者上述指标降低程度更加明显(P＜0.05);观察组患者治疗后PFS、半年生存率、卡氏功能状态评分(KPS)疗效及临床总有效率均明显高于对照组(P＜0.05);观察组患者Ⅲ度及以上毒副反应发生率(11.1%)明显低于对照组(40.0%)(P＜0.05)。结论:扶正固本方联合肝动脉化疗栓塞术治疗原发性肝癌,能够延长患者无进展生存期,抑制血清肿瘤标志物表达,提高患者半年生存率和生存质量,且无明显的药物毒副反应。
Abstract
Objective: To investigate the effect of Fuzheng Guben fomula on progression-free survival and quality of life in patients with primary liver cancer after transcatheter arterial chemoembolization. Methods: A total of 90 patients with primary liver cancer who were treated from January 2019 to March 2020 were randomly divided into control group and observation group. Both groups were treated with hepatic arterial chemoembolization, and the control group was given postoperative acid suppression and liver protection.Symptomatic treatment such as oxygen inhalation,observation group was combined with oral treatment of traditional Chinese medicine Fuzheng Guben fomula after operation,and both groups were treated for 8 weeks.The TCM syndrome scores,cancer antigen 19-9 (CA19-9), alpha-fetoprotein (AFP) levels, progression-free survival (PFS), half-year survival rate,and quality of life were observed in the two groups before and after treatment.The clinical outcomes of the two groups were compared.Efficacy and toxicity of grade Ⅲ and above. Results: After treatment,liver mass,flank pain,abdominal distention,body weight loss,bad habits and vomiting,Shenpi weakness score,CA19-9 and AFP levels in both groups were significantly decreased (P<0.05),and the above indexes in the observation group were decreased.The degree was more obvious (P<0.05); the PFS,half-year survival rate,Karnofsky functional status score (KPS) efficacy and total clinical effective rate in the observation group were significantly higher than those in the control group (P<0.05); The incidence of the above toxic and side effects (11.1%) was significantly lower than that of the control group (40.0%) (P<0.05). Conclusion: Fuzheng Guben fomula combined with transcatheter arterial chemoembolization in the treatment of primary liver cancer could prolong the progression-free survival period,inhibit the expression of serum tumor markers,improve the half-year survival rate and quality life of patients,and there was no obvious drug toxicity.
关键词
原发性肝癌 /
肝动脉化疗栓塞术 /
扶正固本方 /
无进展生存期 /
生存质量 /
肿瘤标志物
{{custom_keyword}} /
Key words
primary liver cancer /
hepatic arterial chemoembolization /
Fuzheng Guben fomula /
progression-free survival /
quality of life /
tumor markers
{{custom_keyword}} /
中图分类号：
R256
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 何津,张大为,王丽莉,等.复方苦参注射液联合恩替卡韦预防原发性肝癌术后复发的临床效果[J].现代中西医结合杂志,2019,28(33):3677-3680.
[2] 王哲,何德山,任柯.中晚期原发性肝癌患者的治疗方案对比研究[J].中国现代普通外科进展,2016,19(1): 69-72.
[3] 张羽飞,朱鸿帆,吴申,等.健脾化瘀法联合肝动脉化疗栓塞术治疗血瘀脾虚型原发性肝癌近期疗效观察[J].现代中西医结合杂志,2020,29(15):1661-1664.
[4] 张国顺,李盛楠,孟冬梅,等.肝动脉化疗栓塞术联合射频消融术治疗原发性肝癌[J].中国老年学杂志,2019,39(8): 1855-1857.
[5] 杜娟琳,李志军,刘红娟,等.肝动脉造影联合栓塞及射频消融术对中晚期肝癌患者血清VEGF 水平的影响[J].现代中西医结合杂志,2019,28(3):302-305.
[6] 陈亚栋,莫春梅,荣震,等.中药联合肝动脉栓塞化疗术(TACE)治疗原发性肝癌研究进展[J].辽宁中医药大学学报,2019,21(1):87-90.
[7] 王树庚,冯亮飞,李丹,等.消癌平注射液联合肝动脉化疗栓塞治疗肝细胞癌疗效观察[J].现代中西医结合杂志,2017,26(33):3731-3734.
[8] 中华人民共和国卫生和计划生育委员会医政医管局.原发性肝癌诊疗规范(2017年版)[J].中华肝脏病杂志,2017,25(12):886-895.
[9] 国家中医药管理局.中医病证诊断疗效标准[M].南京: 南京大学出版社,1994:201-202.
[10] 国家中医药管理局.中药新药临床研究指导原则[M].北京: 中国医药科技出版社,2002:233-237.
[11] 杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85-90,111.
[12] 陆伦根.原发性肝癌的早期筛查及诊断[J].临床肝胆病杂志,2017,33(7):1257-1261.
[13] 唐定,胡智强,邓洲子,等.经导管肝动脉化疗栓塞术联合经皮穿刺微波消融术对肝癌患者血清AFP、CEA、CA19-9水平的影响[J].癌症进展,2019,17(23):2800-2802.
[14] Notarpaolo A,Layese R,Magistri P,et al.Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC[J].J Hepatol,2017,66(3):552-559.
[15] 万赤丹,王国斌.原发性肝癌治疗进展[J].腹部外科,2019,32(1):1-6,22.
[16] 胡泽明,陈彪,钟佳宁,等.原发性肝癌治疗方法的应用进展[J].山东医药,2019,59(9):106-110.
[17] 姜辉,顾胜龙,张玉婷,等.黄芪化学成分和药理作用研究进展[J].安徽中医药大学学报,2020,39(5):93-96.
[18] 吴筱霓,刘伟,何玉华,等.丹参酮ⅡA药理作用研究进展[J].中国药业,2020,29(21):93-97.
[19] 谭静,林红强,王亚茹,等.三棱的化学成分、药理作用及临床应用研究进展[J].特产研究,2018,40(4):109-113.
[20] 邢峰丽,封若雨,孙芳,等.皂角刺的药理作用研究进展[J].环球中医药,2017,10(10):1167-1170.
[21] 吴玲芳,王晓晴,陈香茗,等.白芍化学成分及药理作用研究进展[J].国际药学研究杂志,2020,47(3):175-187.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(3415 KB)
